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Abstract
Background: Past studies have shown that sensitivity of melanoma cells to TRAIL-induced apoptosis is
largely correlated with the expression levels of TRAIL death receptors on the cell surface. However, fresh
melanoma isolates and melanoma tissue sections express generally low levels of death receptors for
TRAIL. The clinical potential of TRAIL in the treatment of melanoma may therefore be limited unless given
with agents that increase the cell surface expression of TRAIL death receptors. 2-Deoxy-D-glucose (2-
DG) is a synthetic glucose analogue that inhibits glycolysis and glycosylation and blocks cell growth. It has
been in clinical evaluation for its potential use as an anticancer agent. In this study, we have examined
whether 2-DG and TRAIL interact to enhance their cytotoxicity towards melanoma cells.
Results: 2-DG did not kill melanoma cells, but enhanced TRAIL-induced apoptosis in cultured melanoma
cells and fresh melanoma isolates. This was associated with increased activation of the caspase cascade and
mitochondrial apoptotic pathway, and was blocked by inhibition of TRAIL-R2, and to a lesser extent,
inhibition of TRAIL-R1. Treatment with 2-DG up-regulated TRAIL death receptors, in particular, TRAIL-
R2, on the melanoma cell surface. Up-regulation of TRAIL-R2 was due to increased transcription that was
not dependent on the transcription factors, p53 and CHOP. Instead, the IRE1α and ATF6 pathways of the
unfolded protein response that were activated by 2-DG appeared to be involved. Moreover, XBP-1, which
is known to be transcriptionally regulated by ATF6 and functionally activated by IRE1α, was found to play
an important role in 2-DG-mediated transcriptional up-regulation of TRAIL-R2 in melanoma cells.
Conclusion:  These results indicate that 2-DG sensitizes human melanoma cells to TRAIL-induced
apoptosis by up-regulation of TRAIL-2 via the ATF6/IRE1α/XBP-1 axis of the unfolded protein response.
They suggest that 2-DG is a promising agent to increase the therapeutic response to TRAIL in melanoma.
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Introduction
TNF-related apoptosis-inducing ligand (TRAIL) appears to
be a promising candidate for cancer therapeutics because
of its ability to preferentially induce apoptosis in malig-
nant cells [1-3]. The potential significance of TRAIL as an
anti-cancer agent has been supported by studies in animal
models showing selective toxicity to human tumor
xenografts but not normal tissues [4,5]. Induction of
apoptosis by TRAIL is mediated by its interaction with two
death domain containing receptors, TRAIL-R1 and -R2 [1-
3]. This in turn orchestrates the assembly of the death-
inducing signaling complex (DISC) that contains adapter
components such as Fas associated death domain (FADD)
that activates initiator caspases, caspase-8 and -10, leading
eventually to activation of effector caspases such as cas-
pase-3 and to apoptosis [1-3]. TRAIL and agonistic anti-
bodies against its death receptors are currently in clinical
evaluation for the treatment of various cancers [6-8].
We have previously shown that sensitivity of cultured
melanoma cells to TRAIL-induced apoptosis is in general
correlated with the levels of the cell surface expression of
TRAIL death receptors, in particular, TRAIL-R2 [9,10].
Subsequent studies demonstrated that fresh melanoma
isolates are relatively resistant to TRAIL-induced apoptosis
due to low levels of TRAIL-death receptor expression [11].
Moreover, melanoma cells selected for TRAIL resistance
by prolonged exposure to TRAIL express substantially
reduced levels of TRAIL-R2 on their surface [12,13]. Stud-
ies on melanoma tissue sections revealed that reduced
TRAIL-R2 expression is associated with disease progres-
sion and a poor prognosis [14]. Taken together, these
studies indicate that melanoma may not respond to treat-
ment with TRAIL unless given with agents that increase
the cell surface expression of TRAIL death receptors, in
particular, TRAIL-R2.
Cancer cells exhibit increased glycolysis and depend on
this metabolic pathway for ATP production [15-17]. As a
consequence, they need a high uptake of glucose and
accelerated rates of glycolysis to survive. This metabolic
feature has evoked much interest in development of glyc-
olytic inhibitors as potential anticancer agents [16,17].
Among them, 2-Deoxy-D-glucose (2-DG) is a synthetic
glucose analogue that is phosphorylated by hexokinase
upon transport into cells, but can not be fully metabolized
[16-18]. 2-DG-6 phosphate accumulates in cells and inter-
feres with glycolysis primarily by inhibition of phosphor-
ylation of glucose by hexokinase, thus causing a depletion
of ATP [16,18]. 2-DG can also cause inhibition of protein
glycosylation that induces endoplasmic reticulum (ER)
stress and gives rise to activation of the unfolded protein
response (UPR) [19,20]. As a single agent, 2-DG has been
shown to inhibit cell growth in a number of cancers, and
to enhance the therapeutic efficacy of chemotherapeutic
drugs in human cancer xenografts [21-23]. On the other
hand, 2-DG has been reported to protect cancer cells from
death by activation of the Akt and mitogen-activated pro-
tein kinase (MAPK) pathways [24].
The cellular response to ER stress, the UPR, consists of
three distinct yet coordinated signaling pathways initiated
respectively by inositol-requiring transmembrane kinase
and endonuclease 1α (IRE1α), activation of transcription
factor 6 (ATF6), and protein kinase-like ER kinase (PERK)
[25-27]. As an adaptive response, the UPR is orchestrated
by transcriptional activation of multiple genes mediated
by IRE1α and ATF6, and a general decrease in translation
initiation mediated by PERK, to alleviate the stress condi-
tion [25-27]. However, excessive and prolonged activa-
tion of the UPR can lead to apoptosis [25-27]. We have
previously shown that, although melanoma cells are not
sensitive to ER stress-induced apoptosis, activation of the
UPR by the glycosylation inhibitor tunicamycin (TM), or
the ER Ca2+ ATPases inhibitor thapsigargin (TG), up-regu-
lates TRAIL-R2 and enhances TRAIL-induced apoptosis in
melanoma cells [28-30].
In view of the potential application of 2-DG and TRAIL in
the treatment of melanoma, we have examined whether
they interact to enhance their toxic effect on melanoma
cells. We show in this report that the combination of 2-
DG and TRAIL enhanced TRAIL-induced apoptosis in
melanoma cell lines and fresh melanoma isolates. This
was primarily due to up-regulation of TRAIL death recep-
tors, in particular, TRAIL-R2 on the melanoma cell sur-
face. Moreover, we demonstrate that up-regulation of
TRAIL-R2 by 2-DG was due to an increase in transcription,
but this is not mediated by p53 or CCAAT/enhancer-bind-
ing protein-homologous protein (CHOP). Instead, the
XBP-1 pathway of the UPR plays an important role in 2-
DG-mediated up-regulation of TRAIL-R2 in melanoma
cells.
Results
2-DG sensitizes melanoma cells to TRAIL-induced 
apoptosis
Our initial studies on two melanoma cell lines, Mel-RM
and MM200, indicated that 2-DG alone did not induce
notable apoptosis, although it inhibited cell proliferation
(Figures 1A &1B). Nevertheless, studies on its effect on
TRAIL-induced apoptosis showed that the combination of
2-DG and TRAIL enhanced sensitivity of the cells to apop-
tosis-induced by TRAIL (Figures 1B &1C). The increase in
TRAIL-induced apoptosis in the presence of 2-DG was
observed as early as 16 hours and reached a peak at 36
hours after treatment (Figure 1B). In association with this,
co-treatment with 2-DG enhanced TRAIL-induced activa-
tion of caspase-8, reduction in ΔΨm, mitochondrial
release of cytochrome c, activation of caspase-3 and cleav-Molecular Cancer 2009, 8:122 http://www.molecular-cancer.com/content/8/1/122
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Figure 1 (see legend on next page)
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age of its substrate PARP (Figures 1D & Figure 2A). It is of
note that the cleaved products of caspase-8 were hardly
detected in MM200 presumably due to relatively low con-
centrations within the cells (Figure 1D). Increased activa-
tion of caspase-3 was shown by both decreased cleavage of
the pro-enzyme of caspase-3, and reduced conversion of
the larger cleaved fragment to smaller ones (Figure 1D).
A summary of studies on the effect of 2-DG on TRAIL-
induced apoptosis in a panel of melanoma cell lines and
cultured melanocytes and fibroblasts is shown in Figure
2B. As expected, co-treatment with 2-DG enhanced
TRAIL-induced apoptosis in all the melanoma lines (p <
0.05). Neither TRAIL nor 2-DG alone induced apoptosis
in melanocytes and fibroblasts, but the combination of
TRAIL and 2-DG resulted in an increase in apoptosis in
both types of normal cells, even though the overall levels
of apoptosis remained low (< 20%) (Figure 2B).
2-DG up-regulates TRAIL-R2 in melanoma cells
Having found that 2-DG enhances TRAIL-induced activa-
tion of caspase-8 (Figure 1D), we examined whether it reg-
ulates the cell surface expression of TRAIL receptors in
melanoma cells. As shown in Figures 3A &3B, 2-DG up-
regulated the expression of TRAIL-R2 on the surface of
Mel-RM and MM200 cells, with a significant increase
being detected at 16 hours, and further increases at 24 and
36 hours after exposure to the compound. The levels of
TRAIL-R1 on the cell surface were also increased by 2-DG,
albeit to a lesser extent, in both cell lines (Figure 3A). In
contrast, 2-DG did not induce any change in the expres-
sion of TRAIL-R3 and -4 on the cell surface (data not
shown). Up-regulation of the cell surface expression of
TRAIL death receptors by 2-DG was confirmed in a panel
of melanoma cell lines (Figure 3C). Treatment with 2-DG
resulted in slight increases in TRAIL-R2 and -R1 on the
surface of melanocytes and fibroblasts (Figure 3C).
TRAIL-induced apoptosis of melanoma cells is primarily
correlated with the levels of TRAIL-R2 expression on the
cell surface [9,10]. We therefore focused on investigation
of the mechanism by which TRAIL-R2 is up-regulated by
2-DG. To this end, we examined if 2-DG regulates TRAIL-
R2 total protein and mRNA levels by Western blotting and
Real time PCR, respectively. As shown in Figure 3D, 2-DG
increased the levels of the TRAIL-R2 total protein that
could be detected by 16 hours after treatment. Figure 3E
shows that treatment with 2-DG up-regulated the levels of
TRAIL-R2 mRNA in both cell lines. The increase in TRAIL-
R2 mRNA levels induced by 2-DG could be inhibited by
pretreatment with actinomycin D (Figure 3E), suggesting
that this was due to a transcriptional increase, rather than
a change in the mRNA stability. Taken together, these
results suggest that up-regulation of the cell surface
expression of TRAIL-R2 by 2-DG results from increased
TRAIL-R2 transcription in melanoma cells.
Sensitization of melanoma cells to TRAIL-induced 
apoptosis by 2-DG is largely mediated by up-regulation of 
TRAIL-R2
The role of up-regulation of TRAIL-R2 in sensitization of
melanoma cells to TRAIL-induced apoptosis by 2-DG was
studied by inhibition of the interaction between TRAIL
and TRAIL-R2 using a TRAIL-R2/Fc chimeric protein. Fig-
ure 4A shows that the TRAIL-R2/Fc chimera significantly
inhibited TRAIL-induced apoptosis in both Mel-RM and
MM200 cells in the absence or presence of 2-DG (p <
0.05). Similarly, 2-DG-mediated sensitization of
melanoma cells to TRAIL-induced apoptosis was blocked
by either the general caspase inhibitor z-VAD-fmk, or the
caspase-8 specific inhibitor z-IETD-fmk (p < 0.05) (Figure
4B & data not shown). In contrast, a TRAIL-R1/Fc chi-
meric protein displayed only minimal inhibitory effects
on sensitization of Mel-RM and MM200 cells to TRAIL-
induced apoptosis (Figure 4C).
To confirm the predominant role of up-regulation of
TRAIL-R2 in sensitization of melanoma cells to TRAIL-
induced apoptosis by 2-DG, we transfected a TRAIL-R2
specific siRNA pool into Mel-RM and MM200 cells. While
TRAIL-R2 siRNA markedly inhibited TRAIL-R2 expression
even in the presence of 2-DG, it inhibited TRAIL-induced
apoptosis in the absence or presence of 2-DG (p < 0.05)
(Figure 4D). Collectively, these results indicate that up-
2-DG sensitizes melanoma cells to TRAIL-induced apoptosis Figure 1 (see previous page)
2-DG sensitizes melanoma cells to TRAIL-induced apoptosis. A, 2-DG inhibits melanoma cell growth. Upper panel: 
Mel-RM and MM200 cells were treated with 2-DG at indicated concentrations for 48 hours. Cell viability was measured by 
MTT assays. Lower panel: Mel-RM and MM200 cells treated with 2-DG (10 μM) for indicated periods were subjected to meas-
urement of viability using MTT assays. B, Mel-RM (upper panel) and MM200 (lower panel) cells were co-treated with 2-DG (10 
μM) and TRAIL (200 ng/ml) for indicated periods before apoptosis was measured by the propidium iodide method using flow 
cytometry. C, Representative flow cytometry histograms of apoptosis assays. Mel-RM and MM200 cells were treated with 2-
DG (10 μM), TRAIL (200 ng/ml), or the combination of both for 24 hours. Apoptosis was measured by the propidium iodide 
method using flow cytometry. D, Whole cell lysates from Mel-RM and MM200 cells treated with the combination of 2-DG (10 
μM) and TRAIL (200 ng/ml) for 16 hours were subjected to Western blot analysis. Note that PARP was detected by an Ab that 
specifically recognizes the cleaved form of PARP.Molecular Cancer 2009, 8:122 http://www.molecular-cancer.com/content/8/1/122
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Figure 2 (see legend on next page)
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regulation of TRAIL-R2 on the cell surface is the main
cause of sensitization of melanoma cells to TRAIL-
induced apoptosis by 2-DG.
2-DG-mediated activation of TRAIL-R2 is independent of 
p53 and CHOP
TRAIL-R2 is a transcriptional target of p53 [31]. However,
up-regulation of TRAIL-R2 by 2-DG in the melanoma cell
lines, ME4405 that lacks p53 expression [32] and Sk-Mel-
28 that harbors mutated p53 [32], suggested that 2-DG-
mediated up-regulation of TRAIL-R2 was independent of
p53 (Figure 2B). To confirm this, we transfected a siRNA
pool for p53 into Mel-RM and MM200 cells. As shown in
Figure 5A, the cells transfected with the p53 siRNA, but
not those with the control siRNA, displayed markedly
lower levels of p53 expression. The reduced expression of
p53 did not have any appreciable effect on 2-DG-medi-
ated up-regulation of TRAIL-R2 on the cell surface and at
the mRNA levels in both cell lines (Figure 5B).
Another transcription factor that is known to regulate
TRAIL-R2 transcription in many cell types is CHOP
[33,34]. We examined if CHOP contributes to 2-DG-
mediated up-regulation of TRAIL-R2 in Mel-RM and
MM200 cells with CHOP stably knocked down by lentivi-
ral infections (Figure 5C). Deficiency in CHOP did not
appear to significantly impact on the increase in TRAIL-R2
induced by 2-DG at both the protein and mRNA levels
(Figure 5D). Together, these results indicate that neither
p53 nor CHOP plays a role in 2-DG-mediated up-regula-
tion of TRAIL-R2 in melanoma cells.
2-DG-mediated up-regulation of TRAIL-R2 is mediated by 
XBP-1
We have previously shown that the IRE1α and ATF6 path-
ways of the UPR are involved in transcriptional up-regula-
tion of TRAIL-R2 by the classic ER stress inducers TM and
TG [29,30]. We tested if 2-DG impinges on ER stress and
activates the UPR in melanoma cells. As shown in Figure
6A, 2-DG up-regulated glucose-regulated protein 78
(GRP78) and the active form of x-box-binding protein-1
(XBP-1) mRNA, two commonly used markers of activa-
tion of the UPR [35,36].
To examine whether any of the UPR signaling pathways
plays a role in up-regulation of TRAIL-R2 by 2-DG, we
transfected siRNA pools for IRE1α, ATF6, and PERK into
Mel-RM and MM200 cells, respectively (Figure 6B). As
shown in Figure 6C, while the basal level of TRAIL-R2
expression was not impacted, up-regulation of TRAIL-R2
by 2-DG on the cell surface was partially inhibited in cells
transfected with the siRNA for IRE1α and ATF6. In con-
trast, inhibition of PERK by siRNA did not alter the expres-
sion of TRAIL-R2 before and after treatment with 2-DG
(Figure 6C).
The IRE1α and ATF6 signaling pathways of the UPR con-
verge on the UPR effector XBP-1, as XBP-1 is transcription-
ally regulated by ATF6, and its activation is mediated by
IRE1α [25-27]. We therefore envisaged that XBP-1 plays a
role in up-regulation of TRAIL-R2 by 2-DG in melanoma
cells. To test this, we examined the effect of 2-DG on
TRAIL-R2 expression in XBP-1-deficient melanoma cell
lines established by stable knockdown with shRNA by
lentiviral infections. Deficiency in XBP-1 inhibited 2-DG-
induced up-regulation of TRAIL-R2 on the cell surface
(Figures 6D &6E). Similarly, it blocked the increase in
TRAIL-R2 transcription induced by 2-DG (Figures 6D
&6E). Collectively, these results indicate that up-regula-
tion of TRAIL-R2 by 2-DG is mediated by XBP-1 as a con-
sequence of activation of the ATF6 and IRE1α pathways of
the UPR.
2-DG up-regulates TRAIL-R2 and enhances TRAIL-induced 
apoptosis in fresh melanoma isolates
Our previous studies have shown that fresh melanoma
isolates, which may reflect more closely the in vivo situa-
tion, are relatively resistance to TRAIL-induced apoptosis
due to low levels of expression of TRAIL death receptors
[11]. We studied if 2-DG can also up-regulate TRAIL-R2 in
fresh melanoma isolates. Freshly isolated melanoma cells,
Mel-CA and Mel-MC were treated with 2-DG for 24 hours.
As shown in Figures 7A and 7B, treatment with 2-DG
A, 2-DG enhances activation of the mitochondrial apoptotic pathway by TRAIL Figure 2 (see previous page)
A, 2-DG enhances activation of the mitochondrial apoptotic pathway by TRAIL. Upper panel: Mel-RM and MM200 
cells treated with the combination of 2-DG (10 μM) and TRAIL (200 ng/ml) for 16 hours were subjected to measurement of 
ΔΨm by JC-1 staining in flow cytometry. The number in each left bottom quadrant represents the percentage of cells with 
reduction in ΔΨm. Lower panel: Cytosolic and mitochondrial fractions of Mel-RM and MM200 cells treated with the combina-
tion of 2-DG (10 μM) and TRAIL (200 ng/ml) for 16 hours were subjected to Western blot analysis. Western blot analysis of 
COX IV or β-actin levels was included to show relative purity of the mitochondrial or cytosolic fractions. B, A summary of 
studies of the effect of 2-DG on TRAIL-induced apoptosis in a panel of melanoma cell lines and a melanocyte 
line. Cells were treated with 2-DG (10 μM) and TRAIL (200 ng/ml) for 24 hours before apoptosis was measured by the pro-
pidium iodide method using flow cytometry. The data shown are either the mean ± SE (A, B, & F), or representative (C, D, & 
E), of three individual experiments.Molecular Cancer 2009, 8:122 http://www.molecular-cancer.com/content/8/1/122
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Figure 3 (see legend on next page)
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increased the levels of TRAIL-R2 on the cell surface as
measured in flow cytometry, and the TRAIL-R2 total pro-
tein levels as detected in Western blot analysis, in both
Mel-CA and Mel-MC cells. Figure 7C shows that neither 2-
DG nor TRAIL induced significant levels of apoptosis (<
20% apoptotic cells) in a panel of fresh melanoma iso-
lates. However, co-treatment with 2-DG and TRAIL
resulted in increases in the percentages of apoptotic cells
(p < 0.05). Sensitization of fresh melanoma isolates to
TRAIL-induced apoptosis by 2-DG was substantially
inhibited by a recombinant TRAIL-R2/Fc chimera (p <
0.05) (Figure 7D), indicating that the effect of 2-DG on
TRAIL-induced apoptosis in fresh melanoma isolates is
largely accounted for by the increase in TRAIL-R2 expres-
sion on the cell surface.
Discussion
The above results show that the combination of 2-DG and
TRAIL, two promising anticancer agents, results in
enhanced killing in cultured melanoma cell lines and
fresh melanoma isolates. This is primarily due to up-regu-
lation of TRAIL-R2 on the melanoma cell surface. Moreo-
ver, they demonstrate that 2-DG-mediated up-regulation
of TRAIL-R2 is due to increased transcription, but this is
not dependent on p53 and CHOP. Instead, the ATF6/
IRE1α/XBP-1 axis of the UPR appears to play an impor-
tant role in up-regulation of TRAIL-R2 induced by 2-DG in
melanoma cells.
TRAIL is currently in clinical evaluation for the treatment
of various cancers [8]. However, our past studies have
shown that fresh isolates of melanoma and melanoma in
tissue sections frequently had low TRAIL death receptor
expression and therefore may be unresponsive to TRAIL
[11,14]. Unlike studies in many other solid cancers, in
which TRAIL-death receptors could be up-regulated by
other clinically relevant therapeutic drugs [37-40], we
have not found these to increase TRAIL death receptor
expression in melanoma. Agents tested have included
DNA-damaging agents, microtubulin-targeting agents,
histone deacetylase inhibitors, and MEK inhibitors [[41],
& data not shown]. Nevertheless, the classic ER stress
inducers, the glycosylation inhibitor TM and the ER Ca2+
ATPases inhibitor TG have been shown to enhance TRAIL-
induced apoptosis in melanoma cells by up-regulation of
TRAIL-R2 via activation of the UPR [29,30], but these
compounds are not clinically applicable due to their tox-
icity towards normal tissues. The ability of 2-DG to up-
regulate TRAIL death receptors in melanoma is therefore
of particular interest, in that fluorodeoxyglucose is com-
monly used in clinical imaging, eg. positron emission
tomography (PET) [42]. In addition, 2-DG alone or in
combination with other therapeutics has been shown to
inhibit tumor cell growth and has been in clinical trial for
its potential as an anticancer agent [16,20-23].
Up-regulation of TRAIL death receptors by 2-DG was asso-
ciated with enhanced apoptotic signaling induced by
TRAIL. This was evidenced by increased activation of cas-
pase-8, reduction in ΔΨm, mitochondrial release of cyto-
chrome C, activation of caspase-3 and cleavage of its
substrate PARP. Caspase-8 and -3 are the major initiator
and effector caspase, respectively, in TRAIL-induced apop-
tosis of melanoma cells [2,3,10], whereas the mitochon-
drial apoptotic pathway is known to play an important
role in TRAIL-induced apoptosis of melanoma [10,43]. In
agreement with our previous finding that TRAIL-R2 is the
dominant TRAIL death receptor in melanoma cells [9,10],
2-DG up-regulates TRAIL death receptors in melanoma cells Figure 3 (see previous page)
2-DG up-regulates TRAIL death receptors in melanoma cells. A, Mel-RM and MM200 cells treated with 2-DG (10 
μM) for indicated periods were subjected to measurement of the cell surface expression of TRAIL-R2 (upper panel) and -R1 
(lower panel) using flow cytometry. The data in y axes represent mean fluorescence intensity (MFI). B, Representative flow 
cytometry histograms showing up-regulation of TRAIL-R2 by 2-DG in melanoma cells. Filled histograms: isotype controls; 
Thick open histograms: TRAIL-R2 expression before treatment; Thin open histograms: TRAIL-R2 expression after treatment 
with 2-DG (10 μM) for 24 hours. C, 2-DG up-regulates TRAIL-R2 and -R1 in a panel of melanoma cell lines, melanocytes, and 
fibroblasts. Cells were treated with 2-DG (10 μM) for 24 hours. The cell surface expression of TRAIL-R2 (upper panel), and -
R1 (lower panel) was measured using flow cytometry. The data in the y axes represent mean fluorescence intensity (MFI). D, 
Whole cell lysates from Mel-RM and MM200 cells treated with 2-DG (10 μM) for indicated periods were subjected to West-
ern blot analysis. E, Left panel: Mel-RM and MM200 cells were treated with the 2-DG (10 μM) for indicated periods. Total 
RNA was isolated and subjected to Real-time PCR analysis for TRAIL-R2 mRNA expression. The relative abundance of mRNA 
expression before treatment was arbitrarily designated as 1. The increases in TRAIL-R2 mRNA at 16, 24, and 36 hours after 
treatment in both cell lines were statistically significant (p < 0.05); Right panel: Mel-RM and MM200 cells were treated with 
actinomycin D (3 μg/ml) for 1 hour before the addition of 2-DG (10 μM) and TRAIL (200 ng/ml) for a further 24 hours. Total 
RNA was isolated and subjected to Real-time PCR analysis for TRAIL-R2 mRNA expression. The relative abundance of mRNA 
expression before treatment was arbitrarily designated as 1. Up-regulation of TRAIL-R2 mRNA by 2-DG was significantly 
inhibited by actinomycin D in both cell lines (p < 0.05). The data shown are either the mean ± SE (A, C, & E), or representative 
(B & D), of three individual experiments.Molecular Cancer 2009, 8:122 http://www.molecular-cancer.com/content/8/1/122
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Figure 4 (see legend on next page)
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inhibition of the interaction of TRAIL with TRAIL-R2, but
not with TRAIL-R1, markedly blocked sensitization of
melanoma cells to TRAIL-induced apoptosis by 2-DG,
indicating that up-regulation of TRAIL-R2 was the main
cause of sensitization of melanoma cells to TRAIL-
induced apoptosis, even though both TRAIL-R1 and -R2
were increased by 2-DG. It is of note, however, the overall
levels of TRAIL-R1 expression on the melanoma cell sur-
face were lower than those of TRAIL-2 before and after
treatment with 2-DG. Therefore, our results do not negate
a potential role of TRAIL-R1 in mediating TRAIL-induced
apoptosis in melanoma cells when it is expressed at rela-
tively higher levels [44].
2-DG-mediated up-regulation of TRAIL-R2 on the
melanoma cell surface was associated with elevated
TRAIL-R2 total protein levels and increased TRAIL-R2
gene transcription. However, p53, which is known to
mediate TRAIL-R2 transcription under many conditions
[31,37], did not appear to play a part in up-regulation of
TRAIL-R2 by 2-DG in melanoma cells. This was initially
suggested by the finding that a p53-null melanoma cell
line (ME4405), and a melanoma cell line carrying
mutated p53 (Sk-Mel-28) displayed increased TRAIL-R2
in response to 2-DG. Further studies with siRNA knock-
down of p53 in melanoma cell lines with wide-type p53
confirmed that inhibition of p53 did not impact on the
up-regulation of TRAIL-R2 by 2-DG. These results, along
with our previous observations that DNA-damaging
agents such as cisplatin and adriamycin that increased the
levels of p53 but did not up-regulate TRAL-R2 in
melanoma cells [[32], & data not shown], suggest that p53
may not be functionally active in melanoma cells in
regard to regulation of TRAIL-R2 expression. We have
found that p53 in melanoma cells are frequently
expressed as the smaller isoforms that aberrantly impact
on the transcriptional activity of p53 [32].
We have previously shown that the ER stress inducers TM
and TG could up-regulateTRAIL-R2 via the ATF6 and
IRE1α pathways of the UPR independently of p53
[29,30]. In addition, the transcription factor CHOP that is
an effector of the UPR also plays a part in up-regulation of
TRAIL-R2 by TM and TG [29,30]. In this study, both the
GRP78 protein and the active form of XBP-1 mRNA, two
commonly used markers of activation of the UPR, were
induced by 2-DG, indicating that, consistent with its
inhibitory effect on glycolysis and glycosylation, 2-DG
activated the UPR in melanoma cells. These results also
suggest that the increase in TRAIL-R2 gene transcription
might be the consequence of activation of UPR target
genes. However, CHOP did not appear to contribute to
increased TRAIL-R2 transcription, as deficiency in CHOP
did not block up-regulation of TRAIL-R2 by 2-DG. It is
unclear why CHOP played a role in up-regulation of
TRAIL-R2 by TM and TG, but failed to do so in 2-DG-
mediated up-regulation of TRAIL-R2, whereas all these
compounds seemingly activated the UPR to comparable
levels in melanoma cells [29,30]. A possible cause for this
is that the cofactor(s) required by CHOP to trigger TRAIL-
R2 transcription is not activated by 2-DG in melanoma
cells. CHOP-mediated activation of Bim transcription is
known to require the formation of CHOP-C/EBP het-
erodimers [45].
As with TM and TG, 2-DG-induced up-regulation of
TRAIL-R2 in melanoma cells was partially inhibited by
siRNA knockdown of IRE1α or ATF6, indicating that these
pathways of the UPR are involved in up-regulation of
TRAIL-R2 by 2-DG. Because XBP-1 is transcriptionally reg-
ulated by ATF6, and is activated by IRE1α [25-27], it
seemed that XBP-1 may play a part in up-regulation of
TRAIL-R2 mediated by these pathways of the UPR. In this
study, deficiency in XBP-1 markedly blocked up-regula-
tion of TRAIL-R2 in melanoma cells, verifying a role of
XBP-1 in 2-DG-mediated up-regulation of TRAIL-R2.
However, the UPR element (UPRE) or ER stress response
element (ERSE) consensus sequence, which is characteris-
tic of promoters of UPR target genes, could not be identi-
fied in the promoter region of the TRAIL-R2 gene (data
Sensitization of melanoma cells to TRAIL-induced apoptosis by 2-DG is largely due to up-regulation of TRAIL-R2 Figure 4 (see previous page)
Sensitization of melanoma cells to TRAIL-induced apoptosis by 2-DG is largely due to up-regulation of TRAIL-
R2. A, Mel-RM and MM200 cells were treated with a TRAIL-R2/Fc chimera (10 μg/ml) before the addition of 2-DG (10 μM) 
and TRAIL (200 ng/ml) for a further 24 hours. Apoptosis was measured by the propidium iodide method using flow cytometry. 
B, Mel-RM and M200 cells were treated the caspase-8 specific inhibitor z-IETD-fmk (30 μM) for 1 hour before the addition of 
2-DG (10 μM) and TRAIL (200 ng/ml) for a further 24 hours. Apoptosis was measured by the propidium iodide method using 
flow cytometry. C, Mel-RM and MM200 cells were treated with a TRAIL-R1/Fc chimera (10 μg/ml) before the addition of 2-
DG (10 μM) and TRAIL (200 ng/ml) for a further 24 hours. Apoptosis was measured by the propidium iodide method using 
flow cytometry. D, Mel-RM and MM200 cells were transfected with the control or TRAIL-R2 siRNA. Left panel: Twenty-four 
hours later, whole cell lysates were subjected to Western blot analysis. Right panel: Twenty-four hours later, the cells were 
treated with 2-DG (10 μM) and TRAIL (200 ng/ml) for a further 24 hours. Apoptosis was measured by the propidium iodide 
method using flow cytometry. The data shown are either the mean ± SE (A, B, C, & the right panel of D), or representative 
(the left panel of D), of three individual experiments.Molecular Cancer 2009, 8:122 http://www.molecular-cancer.com/content/8/1/122
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Figure 5 (see legend on next page)
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not shown). This argues against a direct role of XBP-1 in
activation of transcription of TRAIL-R2 in melanoma cells.
It is conceivable that XBP-1 may activate TRAIL-R2 tran-
scription indirectly via activation of an unknown tran-
scription factor(s). Alternatively, XBP-1-mediated
signaling may cause relief of transcriptional repression on
the TRAIL-R2 promoter. In this regard, inactivation of the
transcription repressor Yin Yang 1 (YY1) has been shown
to lead to up-regulation of TRAIL-R2 in various types of
cells [46]. Interestingly, YY1 is known to be regulated by
O-Linked N-Acetylglucosaminylation (O-GlcNacylatiio-
ioin), which was proposed to be connected with the path-
way of glucose metabolism [47].
The finding that 2-DG could sensitize fresh melanoma
isolates to TRAIL-induced apoptosis by up-regulation of
TRAIL-R2 is of particular importance, for it is known that
fresh melanoma isolates are relatively resistant to TRAIL-
induced apoptosis due to low levels of TRAIL death recep-
tor expression [11]. This may reflect more closely the in-
vivo status of TRAIL death receptor expression in
melanoma cells and their susceptibility to TRAIL-induced
apoptosis. However, treatment with 2-DG also resulted in
a small increase in TRAIL-R2 in normal cells such as
melanocytes and fibroblasts, and caused increased toxic-
ity towards the cells, suggesting that careful evaluation of
low dose of 2-DG or its analogues in combination with
low concentrations of TRAIL is required before investiga-
tions in patients are carried out.
Conclusions
This study shows that 2-DG, a synthetic glucose analogue
that inhibits glycolysis and glycosylation, up-regulates
TRAIL death receptors and enhances TRAIL-induced apop-
tosis in cultured human melanoma cell lines and fresh
melanoma isolates. Moreover, the study demonstrates
that 2-DG-induced up-regulation of TRAIL-R2 is mediated
by the ATF6/IRE1α/XBP-1 axis of the unfolded protein
response independently of p53 and CHOP. Collectively,
our data indicate that 2-DG is a promising agent to
increase the therapeutic response of melanoma to TRAIL.
Methods
Cell Lines
Human melanoma cell lines Mel-RM, MM200, IgR3, Mel-
CV, Mel-FH, Sk-Mel-28, Sk-Mel-110, and ME4405, have
been described previously [9]. They were cultured in
DMEM containing 5% FCS (Commonwealth Serum Lab-
oratories, Melbourne, Australia). The cultured human
melanocyte line HEMn-MP was purchased from Banksia
Scientific (Bulimba, Qld, Australia) and the cells were cul-
tured in medium supplied by Clonetics (Edward Kellar,
Vic., Australia). Human embryonic fibroblasts (FLOW
2000) were cultured in DMEM containing 5% FCS as
described previously [30].
Fresh Melanoma Isolates
Isolation of melanoma cells from fresh surgical specimens
was carried out as described previously [11].
Antibodies, Recombinant Proteins, and Other Reagents
2-DG was purchased from Sigma Chemical Co. (Castle
Hill, Australia). It was dissolved in DMSO to make up a
stock solution of 1 mM. Recombinant human TRAIL and
the TRAIL-R2/Fc chimera were supplied by Genentech Inc.
(San Francisco, CA). The mouse MAbs against TRAIL-R1, -
R2, -R3, and -R4 were also supplied by Genentech Inc.
(San Francisco, CA). The cell-permeable general caspase
inhibitor Z-Val-Ala-Asp(OMe)-CH2F (z-VAD-fmk) and
the caspase-8 specific inhibitor Z-lle-Glu(Ome)-Thr-
Asp(Ome)-CH2F (z-IETD-fmk) were purchased from Cal-
biochem (La Jolla, CA). The rabbit polyclonal Abs against
caspase-3 and -8 were from Stressgen (Victoria, BC, Can-
ada). The rabbit polyclonal Ab against against cleaved
form of PARP was from Cell Signaling Technology (Bev-
erly, MA). The rabbit mAbs against GRP78, XBP-1, IRE1α,
2-DG-mediated up-regulation of TRAIL-R2 is independent of p53 and CHOP Figure 5 (see previous page)
2-DG-mediated up-regulation of TRAIL-R2 is independent of p53 and CHOP. A, Mel-RM and MM200 cells were 
transfected with the control or p53 siRNA. Twenty-four hours later, whole cell lysates were subjected to Western blot analy-
sis. B, Mel-RM and MM200 cells were transfected with the control or p53 siRNA. Twenty-four hours later, cells were treated 
with 2-DG (10 μM) for a further 16 hours. Upper panel: The cell surface expression of TRAIL-R2 was measured using flow 
cytometry. The data in y axes represent mean fluorescence intensity (MFI). Lower panel: Total RNA was isolated and subjected 
to Real-time PCR analysis for TRAIL-R2 mRNA expression. The relative abundance of mRNA expression before treatment 
was arbitrarily designated as 1. C, Whole cell lysates from Mel-RM and MM200 cells transduced with the control or CHOP 
shRNA were subjected to Western blot analysis. The arrow head points to non-specific bands generated by the antibody 
against CHOP. Note that the cells were treated with TM (3 μM) for 16 hours before harvest to better visualize CHOP. D, 
Mel-RM and MM200 cells transduced with the control or CHOP shRNA were treated with 2-DG (10 μM) for 16 hours. Left 
panel: The cell surface expression of TRAIL-R2 was measured using flow cytometry. The data in the y axes represent mean flu-
orescence intensity (MFI). Right panel: Total RNA was isolated and subjected to Real-time PCR analysis for TRAIL-R2 mRNA 
expression. The relative abundance of mRNA expression before treatment was arbitrarily designated as 1. The data shown are 
either the mean ± SE (B & D), or representative (A & C), of three individual experiments.Molecular Cancer 2009, 8:122 http://www.molecular-cancer.com/content/8/1/122
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Figure 6 (see legend on next page)
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ATF6, PERK, and CHOP, were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Isotype control Abs used
were the ID4.5 (mouse IgG2α) mAb against Salmonella
typhi supplied by Dr. L. Ashman (Institute for Medical and
Veterinary Science, Adelaide, Australia), the 107.3 mouse
IgG1 MAb purchased from PharMingen (San Diego, CA),
and rabbit IgG from Sigma Chemical Co (Castle Hill, Aus-
tralia).
Flow Cytometry
Immunostaining on intact and permeabilized cells was
carried out as described previously [9,11]. Analysis was
carried out using a Becton Dickinson (Mountain View,
CA) FACScan flow cytometer.
Apoptosis
Quantitation of apoptotic cells by measurement of sub-
G1 DNA content using the propidium iodide (PI) method
or by Annexin-V staining was carried out as described else-
where [9].
Mitochondrial Membrane Potential (ΔΨm)
Melanoma cells were seeded at 1 × 105 cells/well in 24-
well plates and allowed to reach exponential growth for
24 hours before treatment. Changes in ΔΨm were studied
by staining the cells with the cationic dye, JC-1, according
to the manufacture's instructions (Molecular Probes,
Eugene, OR) as described previously [12].
Western Blot Analysis
Western blot analysis was carried out as described previ-
ously [29,30]. Labeled bands were detected by Immun-
Star™ HRP Chemiluminescent Kit, and images were cap-
tured and the intensity of the bands was quantitated with
the Bio-Rad VersaDoc™ image system (Bio-Rad, Regents
Park, NSW, Australia).
Preparation of Mitochondrial and Cytosolic Fractions
Methods used for subcellular fraction were similar to the
methods described previously [48].
XBP-1 mRNA Splicin
The method used for detection of unspliced and spliced
XBP-1 mRNAs was as described previously [28]. Briefly,
RT-PCR products of XBP-1 mRNA were obtained from
total RNA extracted using primers 5'-cggtgcgcggtgcgtagtct-
gga-3' (sense) and 5'-tgaggggctgagaggtgcttcct-3' (anti-
sense). Because a 26 bp fragment containing an Apa-LI
site is spliced upon activation of XBP-1 mRNA, the RT-
PCR products were digested with Apa-LI to distinguish the
active spliced form from the inactive unspliced form. Sub-
sequent electrophoresis revealed the inactive form as two
cleaved fragments and the active form as a non-cleaved
fragment.
Real-Time PCR
Quantitation of TRAIL-R2 mRNA expression using Real-
Time PCR was performed as described previously. Briefly,
total RNA was isolated, and reverse transcription PCR was
carried out. The resulting cDNA products were used as
templates for real-time PCR assays. Real-time PCR was
performed using the ABI Prism 7700 sequence detection
system (Applied Biosystems, Foster City, CA). For TRAIL-
R2, Twenty-five μl mixtures were used for reaction, which
contains 5 μl cDNA sample (0.5-1 μg/μl), 300 nM forward
primers for TRAIL-R2 (CGCTGCACCAGGTGTGATT), 300
nM reverse primers for TRAIL-R2 (GTGCCGGCTTCG-
CACTGACA), 200 nM probes for TRAIL-R2 (6FAM-CCCT-
XBP-1 plays an important role in up-regulation of TRAIL-R2 by 2-DG Figure 6 (see previous page)
XBP-1 plays an important role in up-regulation of TRAIL-R2 by 2-DG. A, 2-DG activates the UPR in melanoma cells. 
Mel-RM and MM200 cells were treated with 2-DG (10 μM) for indicated periods. Upper panel: Whole cell lysates were sub-
jected to Western blot analysis. Lower panel: RT-PCR products of XBP-1 mRNA from the cells were digested with Apa-LI for 
90 minutes followed by electrophoresis. The longer fragment derived from the active form of XBP1 mRNA and two shorter 
bands derived from the inactive form are indicated. B, Mel-RM and MM200 cells were transfected with the control, IRE1α, 
ATF6, or PERK siRNA. Twenty-four hours later, whole cell lysates were subjected to Western blot analysis. C, Mel-RM (left 
panel) and MM200 (right panel) cells were transfected with the control, IRE1α, ATF6, or PERK siRNA. Twenty-four hours 
later, cells were treated with 2-DG (10 μM) for 24 hours. The cell surface expression of TRAIL-R2 was measured using flow 
cytometry. The data in the y axes represent mean fluorescence intensity (MFI). D, Whole cell lysates from Mel-RM and MM200 
cells transduced with the control or XBP-1 shRNA were subjected to Western blot analysis. E, Left panel: Mel-RM and MM200 
cells transduced with the control or XBP-1 shRNA were treated 2-DG (10 μM) for 24 hours. The cell surface expression of 
TRAIL-R2 was measured using flow cytometry. Filled histograms: isotype controls; Thick open histograms: TRAIL-R2 expres-
sion before treatment; Thin open histograms: TRAIL-R2 expression after treatment with 2-DG (10 μM) for 24 hours. Right 
panel: Total RNA from Mel-RM and MM200 cells transduced with the control or XBP-1 shRNA treated with 2-DG (10 μM) for 
16 hours was isolated and subjected to Real-time PCR analysis for TRAIL-R2. The relative abundance of mRNA expression 
before treatment was arbitrarily designated as 1. Deficiency in XBP-1 significantly blocked up-regulation of TRAIL-R2 mRNA 
by 2-DG (p < 0.05). The data shown are either the mean ± SE (C & the right panel of E), or representative (A, B, D, & the left 
panel of E), of three individual experiments.Molecular Cancer 2009, 8:122 http://www.molecular-cancer.com/content/8/1/122
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GCACCACGACCAGAAACACAG-TAMRA), and 9 mM
MgCI2. Analysis of cDNA for β-actin was included as a
control. The threshold cycle value (Ct) was normalized
against β-actin cycle numbers. The relative abundance of
mRNA expression of a control sample was arbitrarily des-
ignated as 1, and the values of the relative abundance of
mRNA of other samples were calculated accordingly.
Small RNA Interference (siRNA)
Melanoma cells were seeded at 3.5 × 104 cells/well in 24-
well plates and allowed to reach approximately 50% con-
fluence on the day of transfection. The siRNA constructs
used were obtained as the siGENOME SMARTpool rea-
gents (Dharmacon, Lafayette, CO). The siGENOME
SMARTpool IRE1α (M-004951-01-0010), the siGENOME
SMARTpool ATF6 (M-009917-01-0010), the siGENOME
SMARTpool PERK (M-004883-01-0010), the siGENOME
SMARTpool TRAIL-R2 (M-004819-01-0010), the siGE-
NOME SMARTpool p53 (L-003329-00-0005), and the
non-targeting siRNA control, SiConTRolNon-targeting
SiRNA pool (D-001206-13-20) were obtained from Dhar-
macon. Cells were transfected with 50-100 nM siRNA in
Opti-MEM medium (Invitrogen, Carlsbad, CA) with 5%
fetal calf serum using Oligofectamine reagent (Invitrogen,
2-DG up-regulates TRAIL-R2 and enhances TRAIL-induced apoptosis in fresh melanoma isolates Figure 7
2-DG up-regulates TRAIL-R2 and enhances TRAIL-induced apoptosis in fresh melanoma isolates. A, Mel-CA and 
Mel-MC with (thick open histograms) or without (thin open histograms) treatment with 2-DG (10 μM) for 16 hours were sub-
jected to measurement of the cell surface TRAIL-R2 expression in flow cytomety. The filled histograms are isotype controls. B, 
Whole cell lysates from Mel-CA and Mel-MC with or without treatment with 2-DG (10 μM) for 16 hours were subjected to 
Western blot analysis. C, Freshly isolated melanoma cells were treated with 2-DG (10 μM), TRAIL (200 ng/ml), or the combi-
nation of both for 24 hours were subjected to measurement of apoptosis by the propidium iodide method using flow cytome-
try. D, Freshly isolated melanoma cells were treated with a TRAIL-R2/Fc chimera (10 μg/ml) for 1 hour before the addition of 
2-DG (10 μM) and TRAIL (200 ng/ml) for a further 24 hours. Apoptosis was measured by the propidium iodide method using 
flow cytometry. The data shown are either the mean ± SE (C & D), or representative (A & B), of three individual experiments.
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Carlsbad, CA) according to the manufacturer's transfec-
tion protocol. Efficiency of siRNA was measured by West-
ern blot analysis 24 hours after transfection.
Short Hairpin RNA (shRNA) Knockdown
Melanoma cell lines were seeded at 1 × 104 per well in 96
well plates and left to attach overnight. Sigma MISSION®
Lentiviral Transduction Particles for shRNA-mediated
knockdown of CHOP (SHVRS-NM-000100) and Sigma
MISSION® Lentiviral Transduction Particles for shRNA-
mediated knockdown of XBP-1 (SHVRS-NM-
000100)were applied to ~70% confluent cells in the pres-
ence of polybrene (4 or 8 μg/ml) at MOIs of 0.5, 1 or 5 in
100 μl DMEM. After 16 - 24 hours, the culture medium
was replaced and cells were left another 24 hours. Cells
were selected with 2 μg/ml puromycin for 3 days until
mock-transduced controls (polybrene only) were com-
pletely dead. For each transduced melanoma cell line, up
to 4 wells of cells per lentiviral clone were tested for
knockdown via Western Analysis. Cells with lowest
CHOP or XBP-1 levels were expanded for experimental
use.
Statistics
The significance of differences between experimental data
was determined using the two-tailed student's t test for
unpaired observations with Microsoft Excel 2000 soft-
ware.
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ligand; TRAIL-R: TRAIL receptor; 2-DG: 2-Deoxy-D-glu-
cose; ER: endoplasmic reticulum; UPR: the unfolded pro-
tein response; IRE1α: inositol-requiring transmembrane
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